UBS’s Kindred Biosciences, Inc. KIN Stock Holding History

UBS’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$49K	Buy	5,325 +3,433	+181%	+$46.4K	﹤0.01%	6861
2014 Q2	$35K	Buy	+1,892	New	+$32.1K	﹤0.01%	7364
2014 Q1	–	Sell	-1,291	Closed	-$14K	–	10976
2013 Q4	$14K	Buy	+1,291	New	+$15.4K	﹤0.01%	8622

Other funds holding KIN

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's KIN Position: Q3 2014 in Review

UBS increased its Kindred Biosciences, Inc. (KIN) stake by 181% in Q3 2014, buying an estimated $46.4K and bringing the position to 5,325 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #6861.

UBS first reported a position in KIN in Q4 2013 and has held it in 3 quarters since. 56 funds tracked by Wall St. Rank hold KIN as of Q3 2014.

UBS held 5,325 shares of Kindred Biosciences, Inc. worth $49K as of Q3 2014.
UBS bought 3,433 Kindred Biosciences, Inc. shares in Q3 2014, an estimated $46.4K.
Kindred Biosciences, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6861 holding.
UBS first reported a position in Kindred Biosciences, Inc. in Q4 2013 and has held it in 3 quarters since.
56 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.